Aktie 6540 JHL BIOTECH, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren
Inaktiver Wert

Andere Sprachen JHL Biotech, Inc.

Aktien

6540

KYG7863U1076

6540

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Bora Pharmaceutical Laboratories Inc. acquired CDMO Assets of JHL Biotech, Inc. for $100 million.
First Subjects Dosed in Australian Phase I Clinical Study of a Denosumab Biosimilar
JHL Biotech, Inc. Announces First Patient Randomized in the Phase Iii Study of JHL1101 to Treat Diffuse Large B-Cell Lymphoma
JHL Biotech, Inc. Announces China Approves Phase I and Phase III Clinical Trial Application for Bevacizumab Biosimilar to Treat Cancer
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Bevacizumab Biosimilar to Treat Lung Cancer
JHL Biotech Receives Positive CHMP Scientific Advice for Global Phase III Clinical Trial of Proposed Rituximab Biosimilar
Jhl Biotech Announces China Approves Clinical Trial Rituximab Biosimilar to Treat Non-Hodgkin Lymphoma
JHL Biotech, Inc. Appoints Ellis Chu as Chief Financial Officer
JHL Biotech, Inc. announced that it has received $106 million in funding from a group of investors
JHL Biotech Seeks Financing
JHL Biotech, Inc. Announces European Authority, Bulgarian Drug Agency Approves Phase I Clinical Trial Application
JHL Biotech, Inc.(GTSM:6540) dropped from S&P Global BMI Index
JHL Biotech, Inc.'s Board intends to launch an Equity Buyback.
JHL Biotech, Inc. announced that it expects to receive $150 million in funding
JHL Biotech, Inc. Submits Clinical Trial Application in Europe for Proposed Dornase Alfa Biosimilar to Affordably Manage Symptoms of Cystic Fibrosis
JHL Biotech Submits Clinical Trial Application in Europe for Proposed Bevacizumab Biosimilar to Treat Colorectal, Lung, and Ovarian Cancers
JHL Biotech Inc Announces Its Clinical Trial Application for Use of JHL1101 in Phase 1 and Phase 3 Clinical Trials
JHL Doses First Patient In JHL1101 Phase I European Trial
Sanofi Enters into Strategic Biologics Alliance with JHL Biotech in China
JHL Biotech, Inc. announced that it expects to receive TWD 2.55 billion in funding from Sanofi
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 6540 Aktie
  4. Nachrichten JHL Biotech, Inc.
  5. Andere Sprachen